Mga Batayang Estadistika
| LEI | 529900VZKP6N0B8U5F61 |
| CIK | 1183765 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Molecular Templates, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 20, 2025 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or other jurisdiction of incorporation or organiza |
|
| April 24, 2025 |
Exhibit 99.1 Molecular Templates, Inc. DIP Financing Term Sheet P a g e | 1 DIP FINANCING PROPOSAL for: April 20, 2025 ATTN: Craig Jalbert, President, Chief Executive Officer Molecular Templates, Inc. 9301 Amberglen Boulevard Suite 100 Austin, TX 78729 K2 HealthVentures LLC, 855 Boylston Street, 10 Floor, Boston, MA 02116 Molecular Templates, Inc. DIP Financing Term Sheet P a g e | 2 Dear Craig, B |
|
| February 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 20, 2025 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or other jurisdiction of incorporation or organ |
|
| February 26, 2025 |
Amended and restated secured CONTINGENT VALUE RIGHT AGREEMENT Exhibit 10.2 Amended and restated secured CONTINGENT VALUE RIGHT AGREEMENT This AMENDED AND RESTATED SECURED CONTINGENT VALUE RIGHT AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”), dated as of February 20, 2025 (the “Effective Date”) is made by and among Molecular Templates Opco, Inc., a Delaware corporation (“Opco”), Molecular Templates, In |
|
| February 26, 2025 |
LOAN AND SECURITY AGREEMENT BRIDGE LOAN Exhibit 10.1 LOAN AND SECURITY AGREEMENT BRIDGE LOAN This LOAN AND SECURITY AGREEMENT (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, this “Agreement”) dated as of February 20, 2025 (the “Closing Date”) is entered into among Molecular Templates Opco, Inc., a Delaware corporation (“Opco”), Molecular Templates, Inc., a Delaware corporation (“Parent” |
|
| January 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 30, 2024 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or other jurisdiction of incorporation or organ |
|
| December 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 16, 2024 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or other jurisdiction of incorporation or organ |
|
| December 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 4, 2024 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or other jurisdiction of incorporation or organi |
|
| December 4, 2024 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| December 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 27, 2024 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or other jurisdiction of incorporation or organ |
|
| November 26, 2024 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2 |
|
| November 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 25, 2024 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or other jurisdiction of incorporation or organ |
|
| November 18, 2024 |
MTEM / Molecular Templates, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d882996dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7)* MOLECULAR TEMPLATES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 608550208 (CUSIP Number) November 14, 2024 (Date of Event Which Requires Filing This Statement) Check the appropriate box to des |
|
| November 15, 2024 |
SEC FILE NUMBER 001- 32979 CUSIP NUMBER 608550 208 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| November 14, 2024 |
SC 13G/A 1 sc13ga707422mtem11142024.htm AMENDMENT NO. 7 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 7)1 Molecular Templates, Inc. (Name of Issuer) Common Stock, $0.001 pa |
|
| November 12, 2024 |
SC 13G/A 1 p24-3034sc13ga.htm MOLECULAR TEMPLATES, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Molecular Templates, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 608550208 (CUSIP Number) September 30, 2024** (Date of Event Which Requires Filing of This Stat |
|
| October 28, 2024 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| October 17, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| October 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 11, 2024 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or other jurisdiction of incorporation or organi |
|
| October 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 3, 2024 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or other jurisdiction of incorporation or organiz |
|
| September 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 27, 2024 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or other jurisdiction of incorporation or orga |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32979 Mol |
|
| August 14, 2024 |
Molecular Templates, Inc. Reports Second Quarter 2024 Financial Results and Corporate Update EXHIBIT 99.1 Molecular Templates, Inc. Reports Second Quarter 2024 Financial Results and Corporate Update Monotherapy activity of long duration in patients who have progressed on checkpoint therapy via a novel immuno-oncology mechanism of action with PD-L1 ETB (MT-6402) program Early indication of monotherapy activity in CTLA-4 ETB (MT-8421) program through T-reg depletion; no drug-related adverse |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 14, 2024 |
Sub-Sublease, dated May 12, 2024, by and between the Company and TracerDx. Exhibit 10.1 SUB-SUBLEASE THIS SUB-SUBLEASE (this “Sub-Sublease”) is made as of May 12, 2024 (the “Effective Date”) by and between Molecular Templates Opco, Inc., a Delaware corporation, having an address at 9301 Amberglen Blvd., Suite 100, Austin TX 78729 (“Sub-Sublandlord”), and TracerDx., a Delaware corporation, having an address at 180 Varick Street, 6th Floor, New York (“Sub-Subtenant”). RECI |
|
| August 13, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| June 3, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2024 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 3, 2024 |
Molecular Templates, Inc. Provides Interim Update EXHIBIT 99.1 Molecular Templates, Inc. Provides Interim Update Continued monotherapy activity in solid tumors with MT-6402 (PD-L1-targeting ETB) in checkpoint-experienced patients. Early pre-clinical and clinical data demonstrate the potential of MT-0169 (CD38-targeting ETB) in severe immune-mediated diseases. AUSTIN, Texas, June 03, 2024 (GLOBE NEWSWIRE) - Molecular Templates, Inc. (Nasdaq: MTEM, |
|
| May 15, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 15, 2024 |
Molecular Templates, Inc. Reports First Quarter 2024 Financial Results and Corporate Update EXHIBIT 99.1 Molecular Templates, Inc. Reports First Quarter 2024 Financial Results and Corporate Update AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) - Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to crea |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32979 Mo |
|
| May 3, 2024 |
11,010,513 Shares of Common Stock Offered by the Selling Stockholders Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-278932 PROSPECTUS 11,010,513 Shares of Common Stock Offered by the Selling Stockholders The selling stockholders of Molecular Templates, Inc. (“Molecular,” “we,” “us” or the “Company”) identified in this prospectus, including their pledgees, donees, transferees, assigns or other successors in interest (“selling stockholders”), |
|
| May 1, 2024 |
MOLECULAR TEMPLATES, INC. 9301 Amberglen Blvd. Austin, TX 78729 MOLECULAR TEMPLATES, INC. 9301 Amberglen Blvd. Austin, TX 78729 VIA EDGAR May 1, 2024 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: Molecular Templates, Inc. Acceleration Request for Registration Statement on Form S-3 Filed April 25, 2024 File No. 333-278932 Ladies and Gentlemen: Pursuant to Rule 461 under the Securitie |
|
| April 29, 2024 |
SC 13D/A 1 d711815dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 6)* MOLECULAR TEMPLATES, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 608550 109 (CUSIP Number) Patrick G. Enright Managing Member Longitude Capital Partners III, LLC 2 |
|
| April 25, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Molecular Templates, Inc. |
|
| April 25, 2024 |
As filed with the Securities and Exchange Commission on April 25, 2024 S-3 Table of Contents As filed with the Securities and Exchange Commission on April 25, 2024 No. |
|
| April 25, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission |
|
| April 12, 2024 |
Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2024 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| April 2, 2024 |
MTEM / Molecular Templates, Inc. / SANTE HEALTH VENTURES I LP - SC 13D/A Activist Investment SC 13D/A 1 tm2410755d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Molecular Templates, Inc. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class of Securities) 608550208 (CUSIP Number) Jason Brandt c/o Santé Ventures 201 West 5th Street, Suite 1500 Austin, |
|
| April 2, 2024 |
EX-1 2 tm2410755d1ex1.htm EXHIBIT 1 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13D (or any amendment thereto) relating to the Common Stock of Molecular Templates, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13D. Dated: April 2, 2024 Santé Health Ventures I, LP Santé Health V |
|
| March 29, 2024 |
Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update EXHIBIT 99.1 Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update AUSTIN, Texas, March 29, 2024 (GLOBE NEWSWIRE) - Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to cr |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-32 |
|
| March 29, 2024 |
Exhibit 10.3 MOLECULAR TEMPLATES, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY ADOPTED BY THE BOARD OF DIRECTORS: OCTOBER 9, 2017 AMENDED AS OF MAY 31, 2018 FURTHER AMENDED EFFECTIVE AS OF DECEMBER 19, 2019 Each member of the board of directors (the “Board”) of Molecular Templates, Inc. (the “Company”) who is not an employee of the Company or any parent or subsidiary of the |
|
| March 29, 2024 |
Exhibit 10.23 STATE OF TEXAS COUNTY OF TRAVIS This CANCER RESEARCH GRANT CONTRACT (“Contract”) is by and between the Cancer Prevention and Research Institute of Texas (“CPRIT”), hereinafter referred to as the “INSTITUTE”, acting through its Chief Executive Officer, and Molecular Templates, Inc., hereinafter referred to as the “RECIPIENT”, acting through its authorized signing official. RECITALS WH |
|
| March 29, 2024 |
Exhibit 21.1 SUBSIDIARIES OF MOLECULAR TEMPLATES, INC. Subsidiary Jurisdiction Molecular Templates OpCo, Inc. Delaware THLD Enterprises (UK), Limited United Kingdom |
|
| March 29, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2024 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 29, 2024 |
Description of the Company’s securities Exhibit 4.1 DESCRIPTION OF MOLECULAR TEMPLATES, INC.’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2023, Molecular Templates, Inc. had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): common stock, $0.0001 par value per share. Unless the context otherwise requires, |
|
| March 29, 2024 |
As filed with the Securities and Exchange Commission on March 29, 2024 As filed with the Securities and Exchange Commission on March 29, 2024 Registration No. |
|
| March 29, 2024 |
Calculation of Filing Fee Table. EXHIBIT 107 Calculation of Filing Fee Table Form S-8 (Form Type) Molecular Templates, Inc. |
|
| March 28, 2024 |
Exhibit 99.1 Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement AUSTIN, Texas, March 28, 2024 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic thera |
|
| March 28, 2024 |
Regulation FD Disclosure, Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 28, 2024 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or other jurisdiction of incorporation or organiza |
|
| March 28, 2024 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT (I) PURSUANT TO AN EFFECTIVE REG |
|
| March 28, 2024 |
Form of Prefunded Warrant to Purchase Common Stock Exhibit 4.1 THESE SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE BUT HAVE BEEN OR WILL BE ISSUED IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND, ACCORDINGLY, MAY NOT BE TRANSFERRED UNLESS (i) S |
|
| March 28, 2024 |
Amended and Restated Securities Purchase Agreement dated March 28, 2024 Exhibit 10.1 AMENDED AND RESTATED SECURITIES PURCHASE AGREEMENT This Amended and Restated Securities Purchase Agreement (this “Agreement”) is dated as of March 28, 2024 (the “Effective Date”), among Molecular Templates, Inc., a Delaware corporation (the “Company”), and the undersigned Purchasers (as defined below). WHEREAS, the Company previously entered into that certain Securities Purchase Agree |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2024 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| February 14, 2024 |
EX-99.(A) 2 ex-a.htm JOINT FILING AGREEMENT SilverArc Capital Management, LLC SC 13G EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G with respect to the common stock of Molecular Templates, Inc., dated as of February 14, 2024, is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be, filed on b |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Molecular Templates, Inc. (Name of Issuer) Common Stock, par value, $0.001 per share (Title of Class of Securities) 608550208 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 6)1 Molecular Templates, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 608550208 (CUSIP Number |
|
| February 14, 2024 |
US6085502085 / Molecular Templates, Inc. / LYTTON LAURENCE W Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Molecular Templates, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 608550208 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| February 14, 2024 |
SC 13G 1 mtem-sc13g123123.htm SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Molecular Templates, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 608550208 (CUSIP Number) December 31, 2023 (Date of Event which Requires Fili |
|
| February 13, 2024 |
US6085502085 / Molecular Templates, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d40123dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* MOLECULAR TEMPLATES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 608550208 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing This Statement) Check the appropriate box to desi |
|
| January 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 11, 2024 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or other jurisdiction of incorporation or organi |
|
| November 13, 2023 |
Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update EXHIBIT 99.1 Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update AUSTIN, Texas, Nov. 13, 2023 (GLOBE NEWSWIRE) - Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to crea |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3297 |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 13, 2023 |
MOLECULAR TEMPLATES, INC. CLAWBACK POLICY I.Introduction The Board of Directors (the “Board”) of Molecular Templates, Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability. The Board has therefore adopted this policy which provides for the recoupment of certain executive compe |
|
| October 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 27, 2023 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or other jurisdiction of incorporation or organi |
|
| October 24, 2023 |
MTEM / Molecular Templates Inc / Longitude Capital Partners III, LLC - SC 13D/A Activist Investment SC 13D/A 1 d496009dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* MOLECULAR TEMPLATES, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 608550 109 (CUSIP Number) Patrick G. Enright Managing Member Longitude Capital Partners III, LLC 2 |
|
| September 28, 2023 |
Exhibit 10.1 September 26, 2023 Maurizio Voi, M.D. 35 Rogers Avenue Berkeley Heights, NJ 07922 Dear Dr. Voi, On behalf of Molecular Templates, Inc. (“MTEM” or the “Company”), I am pleased to offer you the position of Chief Medical Officer, reporting directly to me. This is a full- time, exempt position, and you will generally work remotely from your home office subject to the specifications outlin |
|
| September 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2023 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or Other Jurisdiction of Incorporation) (Commi |
|
| September 28, 2023 |
EXHIBIT 99.1 Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical Officer AUSTIN, Texas, Sept. 28, 2023 (GLOBE NEWSWIRE) - Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today announced the appo |
|
| September 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| September 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| August 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 28, 2023 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or other jurisdiction of incorporation or organiz |
|
| August 16, 2023 |
MOLECULAR TEMPLATES, INC. 9301 Amberglen Blvd. Austin, TX 78729 MOLECULAR TEMPLATES, INC. 9301 Amberglen Blvd. Austin, TX 78729 VIA EDGAR August 16, 2023 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: Molecular Templates, Inc. Acceleration Request for Registration Statement on Form S-3 Filed August 10, 2023 File No. 333-273864 Ladies and Gentlemen: Pursuant to Rule 461 under the Secu |
|
| August 11, 2023 |
EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MOLECULAR TEMPLATES, INC. Molecular Templates, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY: FIRST: The name of the corporation is Molecular Templates, Inc. (the “Corporation”). SECOND: The date of filing |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 11, 2023 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or other jurisdiction of incorporation or organiz |
|
| August 11, 2023 |
Molecular Templates Announces 1-for-15 Reverse Stock Split EX-99.1 Exhibit 99.1 Molecular Templates Announces 1-for-15 Reverse Stock Split AUSTIN, Texas, August 11, 2023 (GLOBE NEWSWIRE) - Molecular Templates, Inc., (Nasdaq: MTEM) (the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today announced that the Board and stockholders of the Company approved a 1- |
|
| August 10, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 10, 2023 |
Powers of Attorney (included in the signature page of this registration statement). Table of Contents As filed with the Securities and Exchange Commission on August 10, 2023 No. |
|
| August 10, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Molecular Templates, Inc. |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32979 Mol |
|
| August 10, 2023 |
Molecular Templates, Inc. Reports Second Quarter 2023 Financial Results and Business Update EXHIBIT 99.1 Molecular Templates, Inc. Reports Second Quarter 2023 Financial Results and Business Update AUSTIN, Texas, Aug. 10, 2023 (GLOBE NEWSWIRE) - Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to cre |
|
| August 2, 2023 |
Exhibit 10.1 August 1, 2023 Gabriela Gruia, M.D. 350 Albany Street, Apt 2D New York, NY 10280 Dear Dr. Gruia, On behalf of Molecular Templates, Inc. (“MTEM” or the “Company”), I am pleased to offer you the position of interim Chief Medical Officer, reporting directly to me. This is a full-time, exempt position, and you will generally work remotely from your home office subject to the specification |
|
| August 2, 2023 |
Molecular Templates Announces Executive Leadership Changes Exhibit 99.1 Molecular Templates Announces Executive Leadership Changes • Dr. Gabriela Gruia to assume the role of interim Chief Medical Officer • Jason Kim to assume the role of President and Chief Financial Officer • Kristen Quigley to assume the role of Chief Operating Officer • Dr. Grace Kim to assume the role of Chief Strategy Officer and Head of IR AUSTIN, Texas, August 2, 2023 (GLOBE NEWSWI |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 27, 2023 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or other jurisdiction of incorporation or organizat |
|
| July 20, 2023 |
MTEM / Molecular Templates Inc / LYTTON LAURENCE W Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Molecular Templates, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 608550109 (CUSIP Number) July 13, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| July 18, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Molecular Templates, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 608550109 (CUSIP Number) July 12, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to |
|
| July 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| July 13, 2023 |
EX-4.1 Exhibit 4.1 FORM THESE SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE BUT HAVE BEEN OR WILL BE ISSUED IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND, ACCORDINGLY, MAY NOT BE TRANSFERRED |
|
| July 13, 2023 |
EX-4.2 Exhibit 4.2 THE SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES OR IN ANY OTHER JURISDICTION. THE HOLDER MAY NOT OFFER, SELL, TRANSFER, ASSIGN, PLEDGE, HYPOTHECATE, OR OTHERWISE DISPOSE OF OR ENCUMB |
|
| July 13, 2023 |
Molecular Templates Announces Up to $40 Million Private Placement Offering EX-99.1 Exhibit 99.1 Molecular Templates Announces Up to $40 Million Private Placement Offering AUSTIN, Texas, July 13, 2023 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel |
|
| July 13, 2023 |
EX-10.1 Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 12, 2023 (the “Effective Date”), among Molecular Templates, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each a “Purchaser” and, collectively, the “Purchasers”). WHEREAS, the Company and the Purc |
|
| July 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 12, 2023 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or other jurisdiction of incorporation or organizat |
|
| June 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| June 26, 2023 |
MTEM / Molecular Templates Inc / K2 HealthVentures Equity Trust LLC - SC 13G Passive Investment SC 13G 1 brhc20054916sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Molecular Templates, Inc. (Name of Issuer) Common Stock, par value, $0.001 per share (Title of Class of Securities) 608550109 (CUSIP Number) June 16, 2023 (Date of Event Which Requires Filing of this Statement) Check |
|
| June 26, 2023 |
EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G with respect to the Common Stock of Molecular Templates, Inc. |
|
| June 20, 2023 |
EX-10.1 Exhibit 10.1 THIS CONVERTIBLE SECURITY AND THE CONVERSION SHARES ISSUABLE UPON CONVERSION HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THIS CONVERTIBLE SECURITY AND THE CONVERSION SHARES MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, EXCEPT PURSUANT TO AN |
|
| June 20, 2023 |
Molecular Templates Announces Debt Payoff and Restructuring EXHIBIT 99.1 Molecular Templates Announces Debt Payoff and Restructuring Restructuring agreement with K2 HealthVentures (K2HV) to fully discharge and satisfy outstanding debt owed to K2HV for the prepayment of $27.5 million and the granting of contingent value rights and warrants Additional reduction-in-force by approximately 44% as it continues to explore strategic alternatives AUSTIN, Texas, Jun |
|
| June 20, 2023 |
EX-4.1 Exhibit 4.1 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE OFFERED, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, PURSUANT TO AN EXEMPTION FROM |
|
| June 20, 2023 |
Molecular Templates Announces Debt Payoff and Restructuring EX-99.1 Exhibit 99.1 Molecular Templates Announces Debt Payoff and Restructuring • Restructuring agreement with K2 HealthVentures (K2HV) to fully discharge and satisfy outstanding debt owed to K2HV for the prepayment of $27.5 million and the granting of contingent value rights and warrants • Additional reduction-in-force by approximately 44% as it continues to explore strategic alternatives AUSTIN |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2023 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 20, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2023 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 1, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 1, 2023 |
EXHIBIT 99.1 Molecular Templates Announces the FDA Removal of Partial Clinical Hold in the Phase 1 Clinical Trial for MT-0169 and Focuses on Extramedullary Myeloma AUSTIN, Texas, June 01, 2023 (GLOBE NEWSWIRE) - Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biol |
|
| May 26, 2023 |
EXHIBIT 99.1 Molecular Templates to Present on Phase I Dose Escalation Study of MT-6402 at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting AUSTIN, Texas, May 26, 2023 (GLOBE NEWSWIRE) - Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic |
|
| May 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2023 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 15, 2023 |
EXHIBIT 99.1 Molecular Templates, Inc. Reports First Quarter 2023 Financial Results and Business Update Advancing clinical development of MT-6402, MT-8421, and MT-0169, and preclinical activities related to Bristol Myers Squibb collaboration AUSTIN, Texas, May 15, 2023 (GLOBE NEWSWIRE) - Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32979 Molecular Templates, |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001- |
|
| April 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2023 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 3, 2023 |
Calculation of Filing Fee Table. EX-FILING FEES EXHIBIT 107 Calculation of Filing Fee Table Form S-8 (Form Type) Molecular Templates, Inc. |
|
| April 3, 2023 |
As filed with the Securities and Exchange Commission on April 3, 2023 S-8 As filed with the Securities and Exchange Commission on April 3, 2023 Registration No. |
|
| March 31, 2023 |
EXHIBIT 99.1 Molecular Templates, Inc. Reports Fourth Quarter 2022 Financial Results and Business Update Announces strategic reprioritization to focus on clinical development of MT-6402, MT-8421, and MT-0169, and preclinical activities related to BMS collaboration, and related workforce reduction AUSTIN, Texas, March 30, 2023 (GLOBE NEWSWIRE) - Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular T |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-32979 MOLECULAR TEMP |
|
| March 30, 2023 |
Exhibit 21.1 SUBSIDIARIES OF MOLECULAR TEMPLATES, INC. Subsidiary Jurisdiction Molecular Templates OpCo, Inc. Delaware THLD Enterprises (UK), Limited United Kingdom |
|
| March 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 14, 2023 |
MTEM / Molecular Templates Inc / Longitude Capital Partners III, LLC - SC 13D/A Activist Investment SC 13D/A 1 d466123dsc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* MOLECULAR TEMPLATES, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 608550 109 (CUSIP Number) Patrick G. Enright Managing Member Longitude Capital Partners III, LLC 2740 Sand Hill |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 5)1 Molecular Templates, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 608550109 (CUSIP Number |
|
| February 14, 2023 |
EX-99.B Exhibit B POWER OF ATTORNEY The Undersigned, Hugo van Neutegem herewith gives Power of Attorney to Mrs. Nathalie M.A. Isidora-Kwidama, born in Curacao on, holder of a passport issued by the Kingdom of the Netherlands, with number, to represent the Company in the broadest sense of the word and in the best interest of the Company and further to do if were the Undersigned personally present. |
|
| February 14, 2023 |
MTEM / Molecular Templates Inc / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* MOLECULAR TEMPLATES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 608550109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| February 3, 2023 |
MTEM / Molecular Templates Inc / PICTET ASSET MANAGEMENT SA - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Molecular Templates Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 608550109 (CUSIP Number) 12/31/2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| December 2, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2022 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or other jurisdiction of incorporation) (Commis |
|
| December 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2022 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or other jurisdiction of incorporation) (Commis |
|
| November 10, 2022 |
EXHIBIT 99.2 R&D Day Presentation 2022 The Society for Immunotherapy of Cancer?s (SITC) 37th Annual Meeting Forward looking statements 2 Except for statements of historical fact, the statements in this presentation are forward - looking statements, including, but not limited to, statements regarding the future development of our proprietary Engineered Toxin Body (ETB) technology; statements relati |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32979 Molecular Templa |
|
| November 10, 2022 |
Molecular Templates, Inc. Reports Third Quarter 2022 Financial Results EXHIBIT 99.1 Molecular Templates, Inc. Reports Third Quarter 2022 Financial Results AUSTIN, Texas, Nov. 10, 2022 (GLOBE NEWSWIRE) - Molecular Templates, Inc. (Nasdaq: MTEM, ?Molecular Templates,? or ?MTEM?), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), to create novel therapies wit |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 10, 2022 |
Exhibit10.1 FOURTH AMENDMENT TO LEASE This Fourth Amendment To Lease (?Amendment?) is dated as of this 18th day of October, 2022 (the ?Execution Date?), by and between NW Austin Office Partners LLC, a Delaware limited liability company (?Landlord?), and Molecular Templates, Inc., a Delaware corporation (?Tenant?). r e c i t a l s: A. Landlord and Tenant entered into that certain Lease dated as of |
|
| September 1, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2022 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or other jurisdiction of incorporation) (Commissi |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32979 Molecular Templates, |
|
| August 11, 2022 |
Molecular Templates, Inc. Reports Second Quarter 2022 Financial Results EXHIBIT 99.1 Molecular Templates, Inc. Reports Second Quarter 2022 Financial Results AUSTIN, Texas, Aug. 11, 2022 (GLOBE NEWSWIRE) - Molecular Templates, Inc. (Nasdaq: MTEM, ?Molecular Templates,? or ?MTEM?), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), to create novel therapies wi |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| June 6, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2022 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or other jurisdiction of incorporation) (Commission |
|
| May 13, 2022 |
Exhibit10.1 FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT This FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this ?Amendment?) entered into as of April 4, 2022, by and among MOLECULAR TEMPLATES OPCo, INC., a Delaware corporation (?Borrower Representative?, and together with each other Person party to the Agreement as a borrower from time to time, collectively, ?Borrowers?, and each, a ?Borrower |
|
| May 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32979 Molecular Templates, |
|
| May 12, 2022 |
Molecular Templates, Inc. Reports First Quarter 2022 Financial Results EXHIBIT 99.1 Molecular Templates, Inc. Reports First Quarter 2022 Financial Results AUSTIN, Texas, May 12, 2022 (GLOBE NEWSWIRE) - Molecular Templates, Inc. (Nasdaq: MTEM, ?Molecular Templates,? or ?MTEM?), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial resul |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 27, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by |
|
| March 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-32979 MOLECULAR TEMP |
|
| March 29, 2022 |
As filed with the Securities and Exchange Commission on March 29, 2022 As filed with the Securities and Exchange Commission on March 29, 2022 Registration No. |
|
| March 29, 2022 |
Calculation of Filing Fee Table. EXHIBIT 107 Calculation of Filing Fee Table Form S-8 (Form Type) Molecular Templates, Inc. |
|
| March 29, 2022 |
Molecular Templates, Inc. Reports Fourth Quarter 2021 Financial Results EXHIBIT 99.1 Molecular Templates, Inc. Reports Fourth Quarter 2021 Financial Results AUSTIN, Texas, March 28, 2022 (GLOBE NEWSWIRE) - Molecular Templates, Inc. (Nasdaq: MTEM, ?Molecular Templates,? or ?MTEM?), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial re |
|
| March 29, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2022 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 29, 2022 |
Exhibit 10.54 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED AMENDMENT NO. 1 This Amendment No.1 (this ?Amendment?) is effective as of December 2, 2021 (the ?Amendment Effective Date?) and is entered into by and between Molecular Templ |
|
| March 29, 2022 |
Exhibit 21.1 SUBSIDIARIES OF MOLECULAR TEMPLATES, INC. Subsidiary Jurisdiction Molecular Templates OpCo, Inc. Delaware THLD Enterprises (UK), Limited United Kingdom |
|
| March 8, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2022 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or other jurisdiction of incorporation) (Commission |
|
| March 8, 2022 |
Molecular templates Next generation immunotoxins Cowen Presentation Exhibit 99.1 Forward-Looking Statements Except for statements of historical fact, the statements in this presentation are forward-looking statements, including, but not limited to, statements regarding the future development of our proprietary Engineered Toxin Body (ETB) technology; statements relating to the development of MT-511 |
|
| March 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2022 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or other jurisdiction of incorporation) (Commission |
|
| March 2, 2022 |
Exhibit 99.1 Molecular Templates Strengthens Board of Directors and Management Team Industry Veteran Gabriela Gruia, M.D., appointed to Board of Directors Megan Filoon promoted to General Counsel AUSTIN, Texas, March 2, 2022 (GLOBE NEWSWIRE) ? Molecular Templates, Inc. (Nasdaq: MTEM, ?Molecular Templates,? or ?MTEM? or ?the Company?), a clinical-stage biopharmaceutical company focused on the disco |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 4)1 Molecular Templates, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 608550109 (CUSIP Number |
|
| February 11, 2022 |
MTEM / Molecular Templates Inc / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* MOLECULAR TEMPLATES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 608550109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| February 10, 2022 |
MTEM / Molecular Templates Inc / PICTET ASSET MANAGEMENT SA - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Molecular Templates Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 608550109 (CUSIP Number) 12/31/2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu |
|
| December 1, 2021 |
EXHIBIT 99.1 Molecular Templates Provides Corporate Update and Outlines 2022 Milestones Unique PD-L1-mediated immune changes and early signs of anti-tumor activity with MT-6402 Continued dose-finding with MT-5111 and MT-0169 Pipeline advancing with IND planned for CTLA-4 program in 2H22 MTEM to Present at Evercore ISI 4th Annual HealthCONx on December 2nd, 2021 AUSTIN, Texas, Nov. 30, 2021 (GLOBE |
|
| December 1, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2021 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or other jurisdiction of incorporation) (Commis |
|
| November 15, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2021 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 15, 2021 |
Molecular Templates, Inc. Reports Third Quarter 2021 Financial Results EXHIBIT 99.1 Molecular Templates, Inc. Reports Third Quarter 2021 Financial Results AUSTIN, Texas, Nov. 15, 2021 (GLOBE NEWSWIRE) - Molecular Templates, Inc. (Nasdaq: MTEM, ?Molecular Templates,? or ?MTEM?), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial resu |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32979 Molecular Templa |
|
| October 18, 2021 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2021 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or other jurisdiction of incorporation) (Commiss |
|
| September 14, 2021 |
MTEM / Molecular Templates Inc / TAKEDA PHARMACEUTICAL CO LTD - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Molecular Templates, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 608550 109 (CUSIP Number) Takeda Pharmaceutical Company Limited 12-10, Nihonbashi 2-Chome, Chuo-ku, Tokyo 103-8668, Japan Attn: Yoshihiro Nakagawa Te |
|
| August 13, 2021 |
Exhibit 10.2 June 25, 2021 Via E-mail Sean McLennan 5503 Courtyard Drive Austin, TX 78731 Email: [email protected] Dear Sean, On behalf of Molecular Templates, Inc. (?MTEM?), please accept this letter as a modification to your letter agreement with MTEM dated November 4, 2019. All terms outlined in the November 4, 2019 letter agreement and in MTEM?s Proprietary Information and Inventions Agre |
|
| August 13, 2021 |
Exhibit 10.1 November 4, 2019 Sean McLennan 1110 Pine Tree Lane Libertyville, IL 60048 Dear Mr. McLennan, On behalf of Molecular Templates, Inc. (?MTEM? or the ?Company?), I am pleased to offer you the position of Senior Vice President, Finance, reporting directly to me. Total Rewards Annual Salary Your salary will be paid at the rate of $25,000.00 per month ($300,000.00 annualized) less payroll d |
|
| August 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32979 Molecular Templates, |
|
| August 12, 2021 |
Molecular Templates, Inc. Reports Second Quarter 2021 Financial Results EXHIBIT 99.1 Molecular Templates, Inc. Reports Second Quarter 2021 Financial Results AUSTIN, Texas, Aug. 12, 2021 (GLOBE NEWSWIRE) - Molecular Templates, Inc. (Nasdaq: MTEM, ?Molecular Templates,? or ?MTEM?), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial res |
|
| August 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| July 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2021 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or other jurisdiction of incorporation) (Commission |
|
| June 4, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2021 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or other jurisdiction of incorporation) (Commission |
|
| June 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2021 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or other jurisdiction of incorporation) (Commission |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2021 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or other jurisdiction of incorporation) (Commission |
|
| May 14, 2021 |
Exhibit 10.1 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED Execution Version COLLABORATION AGREEMENT by and between Molecular templates, Inc. and BRISTOL-MYERS SQUIBB COMPANY Dated as of February 10, 2021 Table of Contents Page ARTICL |
|
| May 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32979 Molecular Templates, |
|
| May 13, 2021 |
Molecular Templates, Inc. Reports First Quarter 2021 Financial Results EXHIBIT 99.1 Molecular Templates, Inc. Reports First Quarter 2021 Financial Results AUSTIN, Texas, May 13, 2021 (GLOBE NEWSWIRE) - Molecular Templates, Inc. (Nasdaq: MTEM, ?Molecular Templates,? or ?MTEM?), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial resul |
|
| May 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 27, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by |
|
| April 26, 2021 |
SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* MOLECULAR TEMPLATES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 608550109 (CUSIP Number) April 7, 2021 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which |
|
| April 5, 2021 |
EX-99.1 Exhibit 99.1 MOLECULAR TEMPLATES TO PRIORITIZE NEXT-GENERATION ETB CANDIDATES Molecular Templates to Assume Full Rights to TAK-169, Second Generation ETB Targeting CD38 for the Treatment of Multiple Myeloma Development of First-Generation ETB MT-3724 Has Been Discontinued, Company to Focus on Development of Next-Generation ETB Product Candidates Including Clinical Stage MT-5111, TAK-169 an |
|
| April 5, 2021 |
Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2021 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or other jurisdiction of incorporation) (Commission |
|
| March 19, 2021 |
As filed with the Securities and Exchange Commission on March 19, 2021 Registration No. |
|
| March 19, 2021 |
Exhibit 21.1 SUBSIDIARIES OF MOLECULAR TEMPLATES, INC. Subsidiary Jurisdiction Molecular Templates OpCo, Inc. Delaware THLD Enterprises (UK), Limited United Kingdom |
|
| March 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-32979 MOLECULAR TEMP |
|
| March 19, 2021 |
Molecular Templates, Inc. Reports Fourth Quarter 2020 Financial Results EXHIBIT 99.1 Molecular Templates, Inc. Reports Fourth Quarter 2020 Financial Results AUSTIN, Texas, March 18, 2021 (GLOBE NEWSWIRE) - Molecular Templates, Inc. (Nasdaq: MTEM, ?Molecular Templates,? or ?MTEM?), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial re |
|
| March 19, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2021 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| February 22, 2021 |
Molecular Templates, Inc. Announces Proposed Public Offering of Common Stock EX-99.1 EXHIBIT 99.1 Molecular Templates, Inc. Announces Proposed Public Offering of Common Stock AUSTIN, Texas, February 17, 2021 — Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic ther |
|
| February 22, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2021 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or other jurisdiction of incorporation) (Commis |
|
| February 22, 2021 |
EXHIBIT 1.1 Shares of Common Stock Molecular Templates, Inc. UNDERWRITING AGREEMENT February 17, 2021 BofA Securities, Inc. Cowen and Company, LLC Evercore Group L.L.C. As Representatives of the several Underwriters c/o BofA Securities, Inc. One Bryant Park New York, New York 10036 c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 c/o Evercore Group L.L.C. 55 East 52nd Stree |
|
| February 22, 2021 |
Molecular Templates, Inc. Announces Pricing of $75.9 Million Public Equity Offering EX-99.2 EXHIBIT 99.2 Molecular Templates, Inc. Announces Pricing of $75.9 Million Public Equity Offering AUSTIN, Texas, February 18, 2021 — Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biolog |
|
| February 18, 2021 |
6,000,000 Shares Molecular Templates, Inc. Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-242078 PROSPECTUS SUPPLEMENT (To Prospectus dated August 17, 2020) 6,000,000 Shares Molecular Templates, Inc. Common Stock We are offering shares of our common stock, with an aggregate public offering price of $12.65. Our common stock is listed on The Nasdaq Capital Market under the symbol “MTEM.” On February 17, 2021, t |
|
| February 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2021 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or other jurisdiction of incorporation) (Commis |
|
| February 17, 2021 |
SUBJECT TO COMPLETION, DATED FEBRUARY 17, 2021 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-242078 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these |
|
| February 16, 2021 |
EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 16, 2021 PERCEPTIVE ADVISORS LLC |
|
| February 16, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Molecular Templates, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 608550109 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| February 12, 2021 |
SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* MOLECULAR TEMPLATES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 608550109 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| February 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3)1 Molecular Templates, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 608550109 (CUSIP Number |
|
| February 11, 2021 |
EX-99.1 Exhibit 99.1 MOLECULAR TEMPLATES ESTABLISHES MULTI-TARGET COLLABORATION WITH BRISTOL MYERS SQUIBB FOR THE DISCOVERY AND DEVELOPMENT OF NEXT GENERATION ENGINEERED TOXIN BODIES FOR THE TREATMENT OF CANCER Molecular Templates to receive $70 million upfront payment with potential for additional milestone and royalty payments on future sales AUSTIN, TEXAS, February 11, 2021 – Molecular Template |
|
| February 11, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2021 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or other jurisdiction of incorporation) (Commis |
|
| January 7, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2021 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or other jurisdiction of incorporation) (Commissi |
|
| January 7, 2021 |
EX-99.1 Exhibit 99.1 MOLECULAR TEMPLATES Corporate Presentation I January 2021 (NASDAQ: MTEM) Exhibit 99.1 MOLECULAR TEMPLATES Corporate Presentation I January 2021 (NASDAQ: MTEM) Forward-Looking Statements Except for statements of historical fact, the statements in this presentation are forward-looking statements, including, but not limited to, statements regarding the future development of our p |
|
| November 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32979 Molecular Templa |
|
| November 5, 2020 |
EXHIBIT 99.1 Molecular Templates, Inc. Reports Third Quarter 2020 Financial Results and Provides a Corporate Update AUSTIN, Texas, Nov. 05, 2020 (GLOBE NEWSWIRE) - Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxi |
|
| November 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 4, 2020 |
MTEM / Molecular Templates, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* MOLECULAR TEMPLATES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 608550109 (CUSIP Number) October 26, 2020 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| September 18, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Molecular Templates, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 608550 109 (CUSIP Number) Jason Brandt c/o Santé Ventures 201 West 5th Street, Suite 1500 Austin, Texas 78701 (512) 721-1200 (Name, Address and Tel |
|
| August 17, 2020 |
$100,000,000 Molecular Templates, Inc. Common Stock 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-242078 PROSPECTUS $100,000,000 Molecular Templates, Inc. Common Stock We have entered into a sales agreement with Cowen and Company, LLC, or Cowen, relating to the sale of shares of our common stock offered by this prospectus. In accordance with the terms of the sales agreement, we may offer and sell shares of our common stock, $0.001 par |
|
| August 13, 2020 |
CORRESP MOLECULAR TEMPLATES, INC. 9301 Amberglen Blvd, Suite 100 Austin, Texas 78729 August 13, 2020 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jason L. Drory Re: Molecular Templates, Inc. Registration Statement on Form S-3 Filed August 7, 2020 File No. 333-242078 Request for Acceleration Ladies and Gentlemen: P |
|
| August 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32979 Molecular Templates, |
|
| August 7, 2020 |
Exhibit 10.3 Execution Version MOlecular templates, inc. Common Stock (par value $0.001 per share) SALES AGREEMENT August 7, 2020 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Molecular Templates, Inc. (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agree |
|
| August 7, 2020 |
EX-1.2 Exhibit 1.2 Execution Version MOLECULAR TEMPLATES, INC. Common Stock (par value $0.001 per share) SALES AGREEMENT August 7, 2020 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Molecular Templates, Inc. (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. The Company |
|
| August 7, 2020 |
S-3 Table of Contents As filed with the Securities and Exchange Commission on August 7, 2020 Registration No. |
|
| August 6, 2020 |
Molecular Templates, Inc. Reports Second Quarter 2020 Financial Results EXHIBIT 99.1 Molecular Templates, Inc. Reports Second Quarter 2020 Financial Results AUSTIN, Texas, Aug. 06, 2020 (GLOBE NEWSWIRE) - Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported |
|
| August 6, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2020 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| July 20, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): July 20, 2020 Molecular Templates, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-32979 94-3409596 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| July 20, 2020 |
Molecular Templates, Inc. Raises $43 Million in Gross Proceeds Through Its At-the-Market Facility EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Molecular Templates, Inc. Raises $43 Million in Gross Proceeds Through Its At-the-Market Facility AUSTIN, Texas, July 20, 2020 (GLOBE NEWSWIRE) - Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary tar |
|
| June 17, 2020 |
CORRESP MOLECULAR TEMPLATES, INC. 9301 Amberglen Blvd, Suite 100 Austin, Texas 78729 June 17, 2020 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jason L. Drory Re: Molecular Templates, Inc. Registration Statement on Form S-3 Filed June 4, 2020 File No. 333-238937 Request for Acceleration Ladies and Gentleman: Pursu |
|
| June 16, 2020 |
S-3/A Table of Contents As filed with the Securities and Exchange Commission on June 16, 2020 No. |
|
| June 16, 2020 |
CORRESP One Financial Center Boston, MA 02111 617 542 6000 mintz.com June 16, 2020 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jason L. Drory, Division of Corporation Finance, Office of Life Sciences Re: Molecular Templates, Inc. Registration Statement on Form S-3 Filed June 4, 2020 File No. 333-238937 Ladies and |
|
| June 5, 2020 |
SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* MOLECULAR TEMPLATES, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 608550 109 (CUSIP Number) Patrick G. Enright Managing Member Longitude Capital Partners III, LLC 2740 Sand Hill Road, 2nd Floor Menlo Park, CA |
|
| June 4, 2020 |
EX-4.6 Exhibit 4.6 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (the “Agreement”) is made and entered into as of June 4, 2020 by and among Molecular Templates, Inc., a Delaware corporation (the “Company”), and each Selling Stockholder set forth on the signature pages hereto (each, a “Selling Stockholder” and collectively, the “Selling Stockholders”). The Company and the Selling |
|
| June 4, 2020 |
S-3 Table of Contents As filed with the Securities and Exchange Commission on June 4, 2020 No. |
|
| May 28, 2020 |
Submission of Matters to a Vote of Security Holders 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2020 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or other jurisdiction of incorporation) (Commiss |
|
| May 22, 2020 |
EX-10.1 Exhibit 10.1 LOAN AND SECURITY AGREEMENT This LOAN AND SECURITY AGREEMENT (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, this “Agreement”) dated as of May 21, 2020 (the “Closing Date”) is entered into among MOLECULAR TEMPLATES OPCO, INC., a Delaware corporation (“Borrower Representative”, and together with each other Person from time to t |
|
| May 22, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2020 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or other jurisdiction of incorporation) (Commiss |
|
| May 22, 2020 |
MOLECULAR TEMPLATES, INC. ANNOUNCES $45 MILLION DEBT FINANCING FROM K2 HEALTHVENTURES EX-99.1 Exhibit 99.1 MOLECULAR TEMPLATES, INC. ANNOUNCES $45 MILLION DEBT FINANCING FROM K2 HEALTHVENTURES AUSTIN, Texas, May 22, 2020 - Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary targeted biologic therapeutics, engineered toxin bodies (ETB |
|
| May 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32979 Molecular Templates, |
|
| May 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 001-32979 CUSIP NUMBER: 608550109 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2020 ☐ Transition Report on Form 10 -K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Tra |
|
| May 11, 2020 |
Molecular Templates, Inc. Reports First Quarter 2020 Financial Results EXHIBIT 99.1 Molecular Templates, Inc. Reports First Quarter 2020 Financial Results AUSTIN, Texas, May 11, 2020 (GLOBE NEWSWIRE) - Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported f |
|
| May 11, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 11, 2020 Molecular Templates, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-32979 94-3409596 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 7, 2020 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| May 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Molecular Templates, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 608550 109 (CUSIP Number) Jason Brandt c/o Santé Ventures 201 West 5th Street, Suite 1500 Austin, Texas 78701 (512) 721-1200 (Name, Address and Tel |
|
| April 23, 2020 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 13, 2020 |
Exhibit 21.1 SUBSIDIARIES OF MOLECULAR TEMPLATES, INC. Subsidiary Jurisdiction Molecular Templates OpCo, Inc. Delaware THLD Enterprises (UK), Limited United Kingdom |
|
| March 13, 2020 |
THLD / Threshold Pharmaceuticals, Inc. S-8 - - S-8 S-8 As filed with the Securities and Exchange Commission on March 13, 2020 Registration No. |
|
| March 13, 2020 |
Exhibit 10.48 January 3, 2019 Roger J. Waltzman, MD, MBA 425 West 50th Apt. 11F New York, NY 10019 Dear Dr. Waltzman, On behalf of Molecular Templates (“MTEM” or the “Company”), I am pleased to offer you the position of Chief Medical Officer, reporting directly to me. Total Rewards Annual Salary Your salary will be paid at the rate of $33,333.33 per month ($400,000.00 annualized) less payroll dedu |
|
| March 13, 2020 |
Exhibit 10.47 SHARE PURCHASE AGREEMENT This SHARE PURCHASE AGREEMENT (this “Agreement”) dated as of November 18, 2019 (the “Effective Date”) is made by and between Molecular Templates, Inc., a Delaware corporation (the “Company”), and Vertex Pharmaceuticals Incorporated, a corporation organized under the laws of the Commonwealth of Massachusetts (the “Purchaser”). WHEREAS, the Company and the Purc |
|
| March 13, 2020 |
Exhibit 10.46 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED Execution Version MASTER COLLABORATION AGREEMENT BETWEEN VERTEX PHARMACEUTICALS INCORPORATED AND MOLECULAR TEMPLATES, INC. November 18, 2019 MASTER COLLABORATION AGREEMENT Th |
|
| March 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-32979 MOLECULAR TEMP |
|
| March 12, 2020 |
Molecular Templates, Inc. Reports Fourth Quarter 2019 Financial Results EXHIBIT 99.1 Molecular Templates, Inc. Reports Fourth Quarter 2019 Financial Results AUSTIN, Texas, March 12, 2020 (GLOBE NEWSWIRE) - Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reporte |
|
| March 12, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 12, 2020 Molecular Templates, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-32979 94-3409596 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| February 14, 2020 |
THLD / Threshold Pharmaceuticals, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Molecular Templates, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 608550109 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| February 14, 2020 |
EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2020 PERCEPTIVE ADVISORS LLC |
|
| February 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 Molecular Templates, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 608550109 (CUSIP Number |
|
| February 14, 2020 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated February 14, 2020 with respect to the shares of Common Stock of Molecular Templates, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) un |
|
| January 29, 2020 |
THLD / Threshold Pharmaceuticals, Inc. / BB BIOTECH AG - SC 13G Passive Investment SC 13G United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 MOLECULAR TEMPLATES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 608550109 (CUSIP Number) January 24, 2020 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is f |
|
| December 19, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2019 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32979 94-3409596 (State or other jurisdiction of incorporation) (Co |
|
| December 19, 2019 |
EX-10.1 Exhibit 10.1 MOLECULAR TEMPLATES, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY ADOPTED BY THE BOARD OF DIRECTORS: OCTOBER 9, 2017 AMENDED AS OF MAY 31, 2018 FURTHER AMENDED EFFECTIVE AS OF DECEMBER 19, 2019 Each member of the board of directors (the Board) of Molecular Templates, Inc. (the Company) who is not an employee of the Company or any parent or subsidiary |
|
| December 19, 2019 |
Molecular Templates Appoints Corazon Dating Sanders, Ph.D., to its Board of Directors EX-99.1 Exhibit 99.1 Molecular Templates Appoints Corazon Dating Sanders, Ph.D., to its Board of Directors AUSTIN, Texas, December 19, 2019 — Molecular Templates, Inc., (Nasdaq: MTEM) a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics, announced to |
|
| December 5, 2019 |
SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* MOLECULAR TEMPLATES, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 608550 109 (CUSIP Number) Patrick G. Enright Managing Member Longitude Capital Partners III, LLC 2740 Sand Hill Road, 2nd Floor Menlo Park, CA |
|
| November 25, 2019 |
EX-3.1 Exhibit 3.1 MOLECULAR TEMPLATES, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, Eric E. Poma, Ph.D., does hereby certify that: 1. He is the Chief Executive Officer and Chief Scientific Officer of Molecular Templates, Inc., a Delaware corporation (t |
